[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100343351":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":82,"collaborators":84,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":35,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":35,"maxAge":96,"enrollmentInfo":97,"targetDuration":35,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":35,"overallStatus":69,"whyStopped":35,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (LET optimized IMPT)","EXPERIMENTAL","Patients receive LET optimized IMPT for up to 6 weeks.",[13,14,15],"Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy","Other: Quality-of-Life Assessment","Other: Questionnaire Administration",[17,26,32],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"RADIATION","Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy","Given LET optimized IMPT",[9],[23,24,25],"LET-Optimized IMPT","LET-Optimized Intensity Modulated Proton Therapy","Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT)",{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Quality-of-Life Assessment","Ancillary studies",[9],[31],"Quality of Life Assessment",{"type":6,"name":33,"description":28,"armGroupLabels":34,"otherNames":35},"Questionnaire Administration",[9],null,[37],{"name":38,"affiliation":5,"role":39},"David R Grosshans","PRINCIPAL_INVESTIGATOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":35,"email":45},"David Grosshans","CONTACT","713-563-2300","dgrossha@mdanderson.org",[47,67],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Massachusetts General Hospital Cancer Center","NOT_YET_RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-71.05977,42.35843,{"lat":59,"lon":58},[62,65],{"name":63,"role":43,"phone":35,"phoneExt":35,"email":64},"Kaden L Mitra Litzinger","klitzinger@mgh.harvard.edu",{"name":66,"role":39,"phone":35,"phoneExt":35,"email":35},"Torunn Yock",{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":53,"countryCode":54,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030",{"type":56,"coordinates":74},[75,76],-95.36327,29.76328,{"lat":76,"lon":75},[79,81],{"name":80,"role":43,"phone":44,"phoneExt":35,"email":35},"David R. Grosshans",{"name":80,"role":39,"phone":35,"phoneExt":35,"email":35},{"type":83,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[85],{"name":86,"class":87},"National Cancer Institute (NCI)","NIH","100343351","phase-1-let-optimized-impt-in-treating-pediatric-patients-with-ependymoma-100343351",false,"NCT03750513","LET Optimized IMPT in Treating Pediatric Patients With Ependymoma","Pilot Trial of LET Optimized IMPT for Pediatric Patients With Ependymoma","Inclusion Criteria:\n\n* Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III\n* Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)\n* Patient may not receive chemotherapy concurrent with radiation\n* Signed informed consent by patient and\u002For parents or legal guardian\n* Lansky performance status score of 50 -100\n\nExclusion Criteria:\n\n* Patients with previous radiation therapy to the brain\n* Ependymoma of the spine\n* Disseminated ependymoma requiring craniospinal radiation therapy\n* Pregnancy\n* Inability to undergo MR imaging\n* Inability to receive gadolinium-based contrast agent","ALL","22 Years",{"count":98,"type":99},48,"ESTIMATED","INTERVENTIONAL",[102],"PHASE1","This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.",[105,106],"Anaplastic Ependymoma","Ependymoma","2026-05-18",{"date":109,"type":110},"2026-05-20","ACTUAL",{"date":112,"type":110},"2019-04-01",{"date":114,"type":99},"2027-12-31",{"name":5,"class":6},2]